Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities

Experimental Cell Research

Volumn 315, Issue 7, 2009, Pages 1326-1335

  di Tommaso, Anne ^a   Hagen, Jussara ^b   Tompkins, Van ^b   Muniz, Viviane ^b   Dudakovic, Amel ^b   Kitzis, Alain ^a,c   Ladeveze, Veronique ^a   Quelle, Dawn E ^b  

^a UMR 6187 CNRS   (France)

^b UNIVERSITY OF IOWA   (United States)

^c POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Cell cycle arrest; Chromosomal instability; Mdm2; p14ARF; p21; p53; Primate

Indexed keywords

ALANINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTIDINE; PROTEIN P53; THREONINE; VALINE;

ARTICLE; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STABILITY;

PRIMATES; SIMIAE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; FIBROBLASTS; GENES, REPORTER; GENOMIC INSTABILITY; HUMANS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PRIMATES; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 63049117521     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2009.01.010     Document Type: Article

References (54)

1. Lowe S.W., and Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13 (2003) 77-83
2. Quelle D.E., Zindy F., Ashmun R.A., and Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83 (1995) 993-1000
3. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E., Harris C.C., and Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25 (1997) 151-157
4. Ruas M., and Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1378 (1998) F115-F177
5. Carnero A., Hudson J.D., Price C.M., and Beach D.H. p16(INK4A) and p19(ARF) act in overlapping pathways in cellular immortalization. Nat. Cell Biol. 2 (2000) 148-155
6. Weber J.D., Jeffers J.R., Rehg J.E., Randle D.H., Lozano G., Roussel M.F., Sherr C.J., and Zambetti G.P. p53-independent functions of the p19ARF tumor suppressor. Genes Dev. 14 (2000) 2358-2365
7. Eymin B., Leduc C., Coll J.L., Brambilla E., and Gazzeri S. P14(ARF) induces G(2) arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 22 (2003) 1822-1835
8. Kelly-Spratt K.S., Gurley K.E., Yasui Y., and Kemp C.J. p19(Arf) suppresses growth, progression, and metastasis of Hras-driven carcinomas through p53-dependent and -independent pathways. Plos Biol. 2 (2004) 1138-1149
9. Ha L., Ichikawa T., Anver M., Dickins R., Lowe S., Sharpless N.E., Krimpenfort P., DePinho R.A., Bennett D.C., Sviderskaya E.V., and Merlino G. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 10968-10973
10. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6 (2006) 663-673
11. Korgaonkar C., Hagen J., Tompkins V., Frazier A.A., Allamargot C., Quelle F.W., and Quelle D.E. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol. Cell. Biol. 25 (2005) 1258-1271
12. Grisendi S., Bernardi R., Rossi M., Cheng K., Khandker L., Manova K., and Pandolfi P.P. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437 (2005) 147-153
13. Colombo E., Bonetti P., Lazzerini Denchi E., Martinelli P., Zamponi R., Marine J.C., Helin K., Falini B., and Pelicci P.G. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol. Cell. Biol. 25 (2005) 8874-8886
14. Llanos S., Clark P.A., Rowe J., and Peters G. Stabilisation of p53 by p14ARF without relocalization of Mdm2 to the nucleolus. Nat. Cell Biol. 3 (2001) 445-452
15. Reef S., Zalckvar E., Shifman O., Bialik S., Sabanay H., Oren M., and Kimchi A. A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. Mol. Cell 22 (2006) 463-475
16. Itahana K., and Zhang Y. Mitochondrial p32 is a critical mediator of ARF-induced apoptosis. Cancer Cell 13 (2008) 542-553
17. Lee C., Smith B.A., Bandyopadhyay K., and Gjerset R.A. DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res. 65 (2005) 9834-9842
18. Itahana K., Bhat K.P., Jin A.W., Itahana Y., Hawke D., Kobayashi R., and Zhang Y.P. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol. Cell 12 (2003) 1151-1164
19. Sugimoto M., Kuo M.L., Roussel M.F., and Sherr C.J. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol. Cell 11 (2003) 415-424
20. Datta A., Nag A., and Raychaudhuri P. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol. Cell. Biol. 22 (2002) 8398-8408
21. Datta A., Nag A., Pan W., Hay N., Gartel A.L., Colamonici O., Mori Y., and Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J. Biol. Chem. 279 (2004) 36698-36707
22. Brady S.N., Yu Y., Maggi Jr. L.B., and Weber J.D. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol. Cell. Biol. 24 (2004) 9327-9338
23. Tago K., Chiocca S., and Sherr C.J. Sumoylation induced by the Arf tumor suppressor: a p53-independent function. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7689-7694
24. Korgaonkar C., Zhao L., Modestou M., and Quelle D.E. ARF function does not require p53 stabilization or Mdm2 relocalization. Mol. Cell. Biol. 22 (2002) 196-206
25. Weber J.D., Kuo M.L., Bothner B., DiGiammarino E.L., Kriwacki R.W., Roussel M.F., and Sherr C.J. Cooperative signals governing ARF-Mdm2 interaction and nucleolar localization of the complex. Mol. Cell. Biol. 20 (2000) 2517-2528
26. Quelle D.E., Cheng M.G., Ashmun R.A., and Sherr C.J. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16(INK4A) but not by the alternative reading frame protein p19(ARF). Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 669-673
27. Zhang Y., Xiong Y., and Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92 (1998) 725-734
28. Midgley C.A., Desterro J.M.P., Saville M.K., Howard S., Sparks A., Hay R.T., and Lane D.P. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19 (2000) 2312-2323
29. Lohrum M.A., Ashcroft M., Kubbutat M.H., and Vousden K.H. Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization. Curr. Biol. 10 (2000) 539-542
30. Rizos H., McKenzie H.A., Ayub A.L., Woodruff S., Becker T.M., Scurr L.L., Stahl J., and Kefford R.F. Physical and functional interaction of the p14ARF tumor suppressor with ribosomes. J. Biol. Chem. 281 (2006) 38080-38088
31. Paliwal S., Pande S., Kovi R.C., Sharpless N.E., Bardeesy N., and Grossman S.R. Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol. Cell. Biol. 26 (2006) 2360-2372
32. Kalinichenko V.V., Major M.L., Wang X., Petrovic V., Kuechle J., Yoder H.M., Dennewitz M.B., Shin B., Datta A., Raychaudhuri P., and Costa R.H. Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 18 (2004) 830-850
33. Rizos H., Darmanian A.P., Mann G.J., and Kefford R.F. Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene 19 (2000) 2978-2985
34. Tompkins V., Hagen J., Zediak V.P., and Quelle D.E. Identification of novel ARF binding proteins by two-hybrid screening. Cell Cycle 5 (2006) 641-646
35. di Tommaso A., Soler C., Roos C., Kitzis A., and Ladeveze V. The ink4a/arf locus evolution in primates: characterization of three ARF sequences. DNA Cell Biol. 23 (2004) 167-173
36. Chen C., and Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 7 (1987) 2745-2752
37. Tompkins V.S., Hagen J., Frazier A.A., Lushnikova T., Fitzgerald M.P., di Tommaso A., Ladeveze V., Domann F.E., Eischen C.M., and Quelle D.E. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability. J. Biol. Chem. 282 (2007) 1322-1333
38. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K.H., and Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17 (1998) 5001-5014
39. Kuo M.L., den Besten W., Bertwistle D., Roussel M.F., and Sherr C.J. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 18 (2004) 1862-1874
40. Rodway H., Llanos S., Rowe J., and Peters G. Stability of nucleolar versus non-nucleolar forms of human p14(ARF). Oncogene 23 (2004) 6186-6192
41. Pollice A., Sepe M., Villella V.R., Tolino F., Vivo M., Calabro V., and La Mantia G. TBP-1 protects the human oncosuppressor p14ARF from proteasomal degradation. Oncogene (2007)
42. Eymin B., Claverie P., Salon C., Leduc C., Col E., Brambilla E., Khochbin S., and Gazzeri S. p14(ARF) activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol. Cell. Biol. 26 (2006) 4339-4350
43. Wang P., Greiner T.C., Lushnikova T., and Eischen C.M. Decreased Mdm2 expression inhibits tumor development induced by loss of ARF. Oncogene 25 (2006) 3708-3718
44. Khan S.H., Moritsugu J., and Wahl G.M. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3266-3271
45. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 3 (2003) 155-168
46. Matijasevic Z., Steinman H.A., Hoover K., and Jones S.N. MdmX promotes bipolar mitosis to suppress transformation and tumorigenesis in p53-deficient cells and mice. Mol. Cell. Biol. 28 (2008) 1265-1273
47. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., and Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and mdm2. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8292-8297
48. Robertson K.D., and Jones P.A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol. 18 (1998) 6457-6473
49. Pollice A., Nasti V., Ronca R., Vivo M., Iacono M.L., Calogero R., Calabro V., and La Mantia G. Functional and physical interaction of the human ARF tumor suppressor with Tat-binding protein-1. J. Biol. Chem. 279 (2004) 6345-6353
50. Kim W.Y., and Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 127 (2006) 265-275
51. Matheu A., Pantoja C., Efeyan A., Criado L.M., Martin-Caballero J., Flores J.M., Klatt P., and Serrano M. Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev. 18 (2004) 2736-2746
52. Matheu A., Maraver A., Klatt P., Flores I., Garcia-Cao I., Borras C., Flores J.M., Vina J., Blasco M.A., and Serrano M. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448 (2007) 375-379
53. Bothner B., Lewis W.S., DiGiammarino E.L., Weber J.D., Bothner S.J., and Kriwacki R.W. Defining the molecular basis of Arf and Hdm2 interactions. J. Mol. Biol. 314 (2001) 263-277
54. Modestou M., Puig-Antich V., Korgaonkar C., Eapen A., and Quelle D.E. The ARF tumor suppressor inhibits growth through p21-dependent and p21-independent pathways. Cancer Res. 61 (2001) 3145-3150